Latest Ai Platforms News

X2M Connect Limited has announced a non-renounceable entitlement offer to raise approximately $2.26 million, issuing new shares and options to eligible shareholders. The capital raise aims to strengthen the company’s balance sheet and support AI platform enhancements and market expansion.

InteliCare Holdings has raised $1 million through a structured financing deal to extend its cash runway and scale its AI-driven healthcare platform across aged care and disability sectors.

Hiremii Limited has announced the acquisition of Prince Migration & Education, marking a strategic expansion into Australia's East Coast and diversifying its talent acquisition services with migration expertise.

Unith Ltd has raised $1.85 million through a strategic share placement to accelerate the growth of its AI-driven Digital Human platform and expand its global footprint. The capital injection aims to boost platform development, marketing, and partnerships across key regions including Europe, LATAM, MENA, and Australia.

Janison Education Group has renewed its $2 million contract with Chartered Accountants Australia and New Zealand, while debuting its AI-powered platform Jai in a landmark commercial deployment.

SenSen Networks has successfully completed a key contract with Montréal’s Agence de mobilité durable, driving record full-year revenue growth exceeding 20%. The company anticipates strong cash collections into FY26, underscoring its expanding global footprint in AI-driven urban management.

Adveritas Limited has raised $8.5 million through an oversubscribed institutional placement, positioning itself for expansion into the US market and accelerated product development.

Opyl Limited’s AI platform TrialKey has partnered with UK insurer Innovatrix to launch a pioneering parametric insurance product that protects biotech firms from the financial risks of clinical trial failures.

Harvest Technology Group reports it is one year ahead of its 3-Year Pathway to Profit plan, forecasting a significant reduction in EBITDA loss for FY25 and unveiling plans for its AI-powered NEON platform launch in 1H26.

Opyl Limited has secured strategic collaborations with two leading contract research organisations, integrating its AI-driven TrialKey platform into cardiovascular, oncology, and rare disease clinical trials to enhance trial design and accelerate commercial growth.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.